High-quality evidence is lacking to support either surgical or percutaneous exclusion of the left atrial appendage (LAA) to reduce the risk of stroke in patients with nonvalvular A-fib, a new ...

Please provide your email address to receive an email when new articles are posted on . Medtronic announced the launch of its LAA exclusion system in the U.S. after its August 2023 FDA clearance. The ...

In a finding that may have implications for percutaneous left atrial appendage (LAA) occlusion devices, a single-center series suggests that removing or closing off the LAA during cardiac surgery for ...

AtriCure, Inc. ATRC recently announced receipt of regulatory approval from China’s National Medical Products Administration (NMPA) for its AtriClip Left Atrial Appendage (LAA) Exclusion System. This ...

ROCHESTER, MN — Among patients who underwent routine cardiac surgery not related to atrial fibrillation (AF), those who also had prophylactic left atrial appendage (LAA) closure—ostensibly to reduce ...

MASON, Ohio, April 10, 2025--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SAN FRANCISCO -- ...

Atrial fibrillation (AF) is the irregular and rapid beating of the atria. Patients with AF may be asymptomatic or may have symptoms such as fatigue, palpitations and chest pain. They also have an ...

Please provide your email address to receive an email when new articles are posted on . The FDA has issued a safety announcement warning of deaths and other serious adverse events associated with left ...

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and ...